Mark Kaye

Mark Kaye (finance chief) discloses dealings in 3 companies, chiefly Moodys Corp /DE/, Elevance Health, Inc. and CONMED Corp. We count 45 filings; the first trade dates from 1 October 2018 and the latest from 2 October 2026.

Every open-market trade on record is a sale: 14 sales worth €6.7M. The rest of the record consists of 24 share grants and 7 option exercises.

The record was last updated on 6 October 2026 with a share grant (€1.4M) in Elevance Health, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.